{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7509,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": "The slide uses a hub-and-spoke diagram to connect the company brand to three core pillars: team, portfolio, and financials.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/3",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-3",
      "loopMatches": [
        {
          "to": 5,
          "from": 3,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "75b8c386-e12c-4807-b0f3-5e69211b24c3",
          "evidence": "The deck highlights the unmet needs and limitations of current treatments",
          "position": 0,
          "objective": "What is the cost of not investing in Erasca's pipeline?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 5,
          "from": 1,
          "beatId": "7c14303c-7cf7-4655-a29d-3b1346ff20bb",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Setup",
          "beatSlug": "setup",
          "evidence": "Introduction to Erasca's vision and pipeline",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "team_bio",
      "function": "other",
      "notes": "SAB stands for Scientific Advisory Board.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/4",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-4",
      "loopMatches": [
        {
          "to": 5,
          "from": 3,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "75b8c386-e12c-4807-b0f3-5e69211b24c3",
          "evidence": "The deck highlights the unmet needs and limitations of current treatments",
          "position": 0,
          "objective": "What is the cost of not investing in Erasca's pipeline?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 5,
          "from": 1,
          "beatId": "7c14303c-7cf7-4655-a29d-3b1346ff20bb",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Setup",
          "beatSlug": "setup",
          "evidence": "Introduction to Erasca's vision and pipeline",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a Gantt-style chart to represent clinical trial progress.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/5",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-5",
      "loopMatches": [
        {
          "to": 5,
          "from": 3,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "75b8c386-e12c-4807-b0f3-5e69211b24c3",
          "evidence": "The deck highlights the unmet needs and limitations of current treatments",
          "position": 0,
          "objective": "What is the cost of not investing in Erasca's pipeline?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 5,
          "from": 1,
          "beatId": "7c14303c-7cf7-4655-a29d-3b1346ff20bb",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Setup",
          "beatSlug": "setup",
          "evidence": "Introduction to Erasca's vision and pipeline",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for therapeutic intervention.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/6",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-6",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 6,
          "beatId": "6f85f610-214d-4bc5-918d-861526aae38b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Complication",
          "beatSlug": "complication",
          "evidence": "Highlighting the limitations of current treatments and unmet needs",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a matrix structure to map clinical assets to specific indications and trial names.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/7",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-7",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 6,
          "beatId": "6f85f610-214d-4bc5-918d-861526aae38b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Complication",
          "beatSlug": "complication",
          "evidence": "Highlighting the limitations of current treatments and unmet needs",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The diagram shows the MAPK pathway inhibition. The patient population data is presented as a simple table.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/8",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-8",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 6,
          "beatId": "6f85f610-214d-4bc5-918d-861526aae38b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Complication",
          "beatSlug": "complication",
          "evidence": "Highlighting the limitations of current treatments and unmet needs",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "product_demo",
      "function": "present_solution",
      "notes": "The slide uses a KINOMEscan visualization to show selectivity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/9",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-9",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 6,
          "beatId": "6f85f610-214d-4bc5-918d-861526aae38b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Complication",
          "beatSlug": "complication",
          "evidence": "Highlighting the limitations of current treatments and unmet needs",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The chart is a classic waterfall plot used in oncology to show best response per patient/model.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/10",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-10",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 6,
          "beatId": "6f85f610-214d-4bc5-918d-861526aae38b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Complication",
          "beatSlug": "complication",
          "evidence": "Highlighting the limitations of current treatments and unmet needs",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate clinical validation.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/11",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-11",
      "loopMatches": [
        {
          "to": 20,
          "from": 11,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
          "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
          "position": 1,
          "objective": "What are the potential benefits of investing in Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 11,
          "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence",
          "beatSlug": "evidence",
          "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a side-by-side comparison of two market segments, each with a big number metric and supporting clinical/regulatory context.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/12",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-12",
      "loopMatches": [
        {
          "to": 20,
          "from": 11,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
          "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
          "position": 1,
          "objective": "What are the potential benefits of investing in Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 11,
          "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence",
          "beatSlug": "evidence",
          "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "Includes a biological diagram illustrating the RAS protein state transition and mutation impact.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/13",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-13",
      "loopMatches": [
        {
          "to": 20,
          "from": 11,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
          "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
          "position": 1,
          "objective": "What are the potential benefits of investing in Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 11,
          "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence",
          "beatSlug": "evidence",
          "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "traction",
      "function": "analyze_data",
      "notes": "The chart shows lower IC50 values for the Q61X mutation group, suggesting higher sensitivity to the drug.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/14",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-14",
      "loopMatches": [
        {
          "to": 20,
          "from": 11,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
          "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
          "position": 1,
          "objective": "What are the potential benefits of investing in Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 11,
          "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence",
          "beatSlug": "evidence",
          "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Waterfall plots showing best percentage change from baseline for two distinct patient cohorts.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/15",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-15",
      "loopMatches": [
        {
          "to": 20,
          "from": 11,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
          "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
          "position": 1,
          "objective": "What are the potential benefits of investing in Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 11,
          "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence",
          "beatSlug": "evidence",
          "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "Includes a Kaplan-Meier survival curve comparing existing standard-of-care options.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/16",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-16",
      "loopMatches": [
        {
          "to": 20,
          "from": 11,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
          "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
          "position": 1,
          "objective": "What are the potential benefits of investing in Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        },
        {
          "to": 18,
          "from": 16,
          "name": "Voice Of Customer",
          "slug": "51-voice-of-customer",
          "bestFor": "Product strategy, customer experience, market research",
          "matchId": "15811b97-f573-4124-b3e9-b52968ac14b4",
          "evidence": "The deck presents case studies and testimonials from patients and clinicians",
          "position": 2,
          "objective": "What do patients and clinicians need from cancer treatments?",
          "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
          "confidence": 0.6,
          "description": "Let customer quotes and feedback drive the narrative and validate the insight"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 11,
          "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence",
          "beatSlug": "evidence",
          "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "testimonial",
      "function": "illustrate_case",
      "notes": "The slide uses a 'before-after' visual comparison to demonstrate clinical efficacy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/17",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-17",
      "loopMatches": [
        {
          "to": 20,
          "from": 11,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
          "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
          "position": 1,
          "objective": "What are the potential benefits of investing in Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        },
        {
          "to": 18,
          "from": 16,
          "name": "Voice Of Customer",
          "slug": "51-voice-of-customer",
          "bestFor": "Product strategy, customer experience, market research",
          "matchId": "15811b97-f573-4124-b3e9-b52968ac14b4",
          "evidence": "The deck presents case studies and testimonials from patients and clinicians",
          "position": 2,
          "objective": "What do patients and clinicians need from cancer treatments?",
          "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
          "confidence": 0.6,
          "description": "Let customer quotes and feedback drive the narrative and validate the insight"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 11,
          "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence",
          "beatSlug": "evidence",
          "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide highlights US FDA Fast Track designation and superior PFS performance.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/18",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-18",
      "loopMatches": [
        {
          "to": 20,
          "from": 11,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
          "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
          "position": 1,
          "objective": "What are the potential benefits of investing in Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        },
        {
          "to": 18,
          "from": 16,
          "name": "Voice Of Customer",
          "slug": "51-voice-of-customer",
          "bestFor": "Product strategy, customer experience, market research",
          "matchId": "15811b97-f573-4124-b3e9-b52968ac14b4",
          "evidence": "The deck presents case studies and testimonials from patients and clinicians",
          "position": 2,
          "objective": "What do patients and clinicians need from cancer treatments?",
          "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
          "confidence": 0.6,
          "description": "Let customer quotes and feedback drive the narrative and validate the insight"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 11,
          "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence",
          "beatSlug": "evidence",
          "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart is a mirrored bar chart (diverging bar chart) showing AE frequency by grade.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/19",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-19",
      "loopMatches": [
        {
          "to": 20,
          "from": 11,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
          "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
          "position": 1,
          "objective": "What are the potential benefits of investing in Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 11,
          "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence",
          "beatSlug": "evidence",
          "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a 2D grid to map dose combinations against regulatory requirements (Project Optimus).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/20",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-20",
      "loopMatches": [
        {
          "to": 20,
          "from": 11,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
          "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
          "position": 1,
          "objective": "What are the potential benefits of investing in Erasca's pipeline?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 11,
          "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence",
          "beatSlug": "evidence",
          "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide outlines two distinct clinical trial programs (SEACRAFT-1 and SEACRAFT-2) with specific stages, patient cohorts, and regulatory endpoints.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/21",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-21",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 21,
          "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": null,
          "evidence": "Describing the potential benefits of Erasca's pipeline",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The diagram shows the RAS/MAPK signaling pathway with ERAS-007 targeting ERK.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/22",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-22",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 21,
          "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": null,
          "evidence": "Describing the potential benefits of Erasca's pipeline",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "solution",
      "function": "present_solution",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/23",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-23",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 21,
          "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": null,
          "evidence": "Describing the potential benefits of Erasca's pipeline",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The chart is a Kaplan-Meier survival curve comparing a control arm to an experimental arm (EC).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/24",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-24",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 21,
          "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": null,
          "evidence": "Describing the potential benefits of Erasca's pipeline",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Shows efficacy data for ERAS-007 in combination with Encorafenib and Cetuximab.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/25",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 21,
          "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": null,
          "evidence": "Describing the potential benefits of Erasca's pipeline",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes waterfall plot and swimmer plot for clinical trial results.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/26",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-26",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 21,
          "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": null,
          "evidence": "Describing the potential benefits of Erasca's pipeline",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "Data cutoff 23MAR2023. TRAE = Treatment-related Adverse Event. EC = Encorafenib + Cetuximab.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/27",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-27",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 21,
          "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": null,
          "evidence": "Describing the potential benefits of Erasca's pipeline",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The diagram shows the RAS/MAPK/PI3K signaling pathway. ERAS-801 is shown as an EGFR inhibitor.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/28",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-28",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 21,
          "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": null,
          "evidence": "Describing the potential benefits of Erasca's pipeline",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM compared to other indications.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/29",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-29",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 21,
          "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": null,
          "evidence": "Describing the potential benefits of Erasca's pipeline",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 30,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a biological diagram to illustrate EGFR mutations in GBM.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/30",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-30",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 30,
          "from": 21,
          "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": null,
          "evidence": "Describing the potential benefits of Erasca's pipeline",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority in mouse models.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/31",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-31",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 38,
          "from": 31,
          "beatId": "655f0f34-999c-4f6f-9941-38fe6e021aa5",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Market Sizing",
          "beatSlug": null,
          "evidence": "Estimating the market potential of Erasca's treatments",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
      "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
      "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
      "authorId": "erasca",
      "authorName": "Erasca",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 32,
      "slideType": "product_demo",
      "function": "show_traction",
      "notes": "The chart is a Kaplan-Meier survival plot comparing three treatment groups.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/32",
      "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
      "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-32",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 38,
          "from": 31,
          "beatId": "655f0f34-999c-4f6f-9941-38fe6e021aa5",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Market Sizing",
          "beatSlug": null,
          "evidence": "Estimating the market potential of Erasca's treatments",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}